| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CYSTIC FIBROSIS |
1 Department of Medicine, University of Washington Medical Center, Seattle, WA, USA
2 Department of Pediatrics, University of Washington Medical Center, Seattle, WA, USA
Correspondence to:
Correspondence to:
Dr C H Goss
Assistant Professor of Medicine, University of Washington Medical Center, Campus Box 356522, 1959 NE Pacific, Seattle, WA 98195, USA; goss{at}u.washington.edu
Background: Stenotrophomonas maltophilia (SM) is a Gram-negative non-fermenting bacteria cultured from the sputum of patients with cystic fibrosis (CF). To date, no information is available regarding the effect of this organism on lung function in CF.
Methods: A cohort study was conducted to assess the effect of SM on lung function among CF patients aged 
6 years in the CF Foundation National Patient Registry from 1994 to 1999. Repeated measures regression was used to assess the association between SM and lung function.
Results: The cohort consisted of 20 755 patients with median age at entry of 13.8 years and median follow up time of 3.8 years; 2739 patients (13%) were positive at least once for SM and 18 016 (87%) were never positive. After adjusting for sex, height and age, patients with SM had a mean forced expiratory volume in 1 second which was 0.09 l less (95% CI 0.05 to 0.14) than those without SM. The mean rate of decline associated with SM positivity was 0.025 l/year (95% CI 0.012 to 0.037) but, after adjusting for confounders (sex, height, weight, intravenous antibiotic courses, hospital admissions, pancreatic insufficiency, and Pseudomonas aeruginosa and Burkholderia cepacia status), the mean rate of decline decreased to 0.008 l/year (–0.008, 95% CI –0.019 to 0.003).
Conclusions: Although CF patients with SM have worse lung function at the time of positivity, no association was found between SM and increased rate of decline after controlling for confounders.
Keywords: Stenotrophomonas maltophilia; cystic fibrosis; lung function; outcome
This article has been cited by other articles:
|
|
 |
|
  I Kukavica-Ibrulj and R C Levesque Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies Lab Anim, October 1, 2008; 42(4): 389 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S. Elborn Identification and management of unusual pathogens in cystic fibrosis J R Soc Med, July 1, 2008; 101(Supplement_1): 2 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Harris, M. A. De Groote, S. D. Sagel, E. T. Zemanick, R. Kapsner, C. Penvari, H. Kaess, R. R. Deterding, F. J. Accurso, and N. R. Pace Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis PNAS, December 18, 2007; 104(51): 20529 - 20533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H Goss and J. L Burns Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis Thorax, April 1, 2007; 62(4): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Besier, C. Smaczny, C. von Mallinckrodt, A. Krahl, H. Ackermann, V. Brade, and T. A. Wichelhaus Prevalence and Clinical Significance of Staphylococcus aureus Small-Colony Variants in Cystic Fibrosis Lung Disease J. Clin. Microbiol., January 1, 2007; 45(1): 168 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Davis Cystic Fibrosis Since 1938 Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 New bacteria in cystic fibrosis Arch. Dis. Child., May 1, 2005; 90(5): 444 - 444. [Full Text] [PDF]
|
|
|
|
|
|
J S Elborn Difficult bacteria, antibiotic resistance and transmissibility in cystic fibrosis Thorax, November 1, 2004; 59(11): 914 - 915. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
